Eli Lilly (LLY)

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.

These stocks may deliver gains during any market environment.

Infectious disease could fuel Eli Lilly's next growth phase.

Marvell’s leap into the S&P 500 caps a sharp AI-chip rebound that helped steady U.S. stocks, today, June 8, 2026.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.1% in the afternoon session after the company reported positive Phase 3 ...

Zealand Pharma's stock is cratering today after disappointing results from a late-stage trial of its GLP-1 dual-receptor agonist drug.

Eli Lilly emerged as the "clear winner" from the ADA meeting last weekend in New Orleans, an analyst said following the event.

How does an average annual gain of 18% over the past decade sound?

Eli Lilly reports Foundayo delivered significant weight loss across menopausal stages, with up to 14.4% reductions at 72 weeks.

Getting exposure to high-profile IPOs is easier than ever through low-cost index funds and ETFs.

Investor Jordi Visser says Eli Lilly could become the world's largest company and AI leader within five years due to its AI advantage.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...

The Vanguard Dividend Appreciation ETF is the perfect fit for investors looking to build a portfolio around high-quality companies that pay growing dividends.

Novo Nordisk could maintain this latest early-mover advantage longer than you think.

Micron has had a turnaround for the ages, going from a free cash flow negative company to a $1 trillion valuation in a little over a year.

Eli Lilly just announced a trio of acquisitions that will allow it to build a new business focused on infectious diseases.

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

International growth could help push Lilly even higher.

Investors appear to have left Novo Nordisk behind as they focus on Eli Lilly; that could be a mistake.

The stock market appears to be rotating into health care.

One fund backs medical breakthroughs and charity, while the other favors industry giants and steady income. Compare their strategies and portfolio makeup.

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.